Latest News and Press Releases

BERLIN, July 15, 2008 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) announced today that the European Commission has granted the company marketing authorization for Firazyr(r) (Icatibant) in the treatment...

Shire Offers Euro 6.25 Per Share and Further Subscribes For Shares in a Capital Increase Takeover by Shire Ensures Successful Commercialization of...

BERLIN, June 23, 2008 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) announced today that following last week's communication with the U.S. Food and Drug Administration (FDA), the company will submit a...

BERLIN, May 15, 2008 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) reported financial results for the first quarter ended March 31, 2008. Under International Financial Reporting Standards (IFRS), revenues...

BERLIN, April 24, 2008 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) announced today that the company has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the...

BERLIN, April 24, 2008 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) has received a not approvable letter from the FDA for its New Drug Application (NDA) for Icatibant in the treatment of hereditary...

BERLIN and FORT COLLINS, Colo., April 10, 2008 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) and PR Pharmaceuticals announced today a license and development agreement between Jerini Ophthalmic, Inc. (JOI),...

Highlights: * EUR 38.2 million in cash and cash equivalents as of December 31, 2007 * Revenues in 2007 increased by 42 percent to EUR 18.6 million * Marketing applications for...

BERLIN, Dec. 21, 2007 (PRIME NEWSWIRE) -- On December 20, 2007, Jerini AG (FSE:JI4) received filing acceptance of its New Drug Application (NDA) for Icatibant in the treatment of hereditary angioedema...

BERLIN, Dec. 21, 2007 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) announced today that its New Drug Application (NDA) for Icatibant in the treatment of hereditary angioedema (HAE) has been accepted by the...